Enicepatide clinical trials
Also written CT-388 and RO7795068.
How each study uses enicepatide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enicepatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2026 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test enicepatide.
- Apr 2027A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsPhase 1 · Hoffmann-La Roche
- Nov 2027A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightPhase 2 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses enicepatide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesRecruitingPhase 3Hoffmann-La RocheNCT07351058Written as Enicepatide
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesRecruitingPhase 3Hoffmann-La RocheNCT07351045Written as Enicepatide
- A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseNot yet recruitingPhase 3Hoffmann-La RocheNCT07918846Written as Enicepatide
- A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruitingPhase 3Hoffmann-La RocheNCT07670416Written as Enicepatide
- A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNot yet recruitingPhase 2Hoffmann-La RocheNCT07589686Written as Enicepatide
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsNot yet recruitingPhase 3Hoffmann-La RocheNCT07889648Written as Enicepatide
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsActive, not recruitingPhase 1Hoffmann-La RocheNCT07626515Written as Enicepatide
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusCompletedPhase 2Carmot Therapeutics, Inc.NCT06628362Written as Enicepatide
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompletedPhase 2Carmot Therapeutics, Inc.NCT06525935Written as Enicepatide
- A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes MellitusCompletedPhase 1Carmot Therapeutics, Inc.NCT04838405Written as CT-388
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered2
- A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular DiseaseNov 5, 2026NCT07918846
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsOct 22, 2026NCT07889648
Codes
What other systems call enicepatide · ClinicalTrials.gg INT017329
- UNII (FDA) MTP9QR7GYFENICEPATIDEOne source FDA
- NCI Thesaurus C224735EnicepatideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MTP9QR7GYF | ENICEPATIDE | One source FDA |
| NCI Thesaurus | C224735 | Enicepatide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.